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ABSTRACT 
This thesis demonstrates the applicability of pharmacoeconomic analysis for two 
drug therapies used in the palliative treatment of breast cancer. The 
pharmacoeconomic evaluation explores the techniques that would be used in 
performing a cost-effectiveness analysis of anastrozole and megestrol acetate 
therapies. The thesis discusses the methods for collecting, interpreting, and 
extrapolating clinical and economic data. The analytical techniques include: 
measuring the effectiveness of breast cancer therapies, applying clinical decision 
analysis methods to produce a decision tree, reviewing clinical trial data and 
examining the clinical findings with the numbers needed to treat approach, 
applying survival data to a pharmacoeconomic evaluation, the valuation of 
resource items, constructing and using a costs and outcomes table, and calculating 
the cost-effectiveness ratio and the incremental cost-effectiveness ratio. 
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Chapter 1 
Introduction 
This thesis will illustrate the methodologies that might be used in a 
pharmacoeconomic evaluation of two drugs for the palliative treatment of breast 
cancer. The technical aspects of the pharmacoeconomic evaluation will follow the 
Canadian Coordinating Office of Health Technology Assessment, Guidelines for 
Economic Evaluation of Pharmaceuticals: Canada (CCOHT A, 1997). The 
technical areas will include: the perspective of the evaluation, the measurement of 
costs and outcomes, decision analysis, the analytical time horizon, data sources, 
uncertainty of data, survival analysis, discounting of costs and outcomes, 
constructing a cost and outcomes cohort table, and the application of sensitivity 
analyses (CCOHT A, 1997). 
The purpose of this thesis is to develop the analytical techniques needed to 
perform a cost-effectiveness analysis of anastrozole and megestrol acetate 
therapies. Hopefully, by developing the analytical techniques, more 
pharmacoeconomic evaluations on palliative breast cancer therapies will be 
performed. High quality pharmacoeconomic evaluations will play an important 
role in encouraging effective, efficient, and equitable drug therapy selection. 
Chapter 1 will provide a short discussion on health and economics, 
pharmacoeconomics, and palliative breast cancer treatments. Chapter 2 will 
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review the components of the cost-effectiveness ratio, the incremental cost-
effectiveness ratio, and the structuring of clinical data into a decision model. 
Chapter 3 will describe the problems with using randomized clinical trial data in a 
pharmacoeconomic evaluation. Chapter 4 will review the handling of survival 
information. Chapter 5 will describe the steps involved in collecting, tabulating, 
and presenting cost data. A costs and outcomes table for combining clinical and 
economic data will be provided. Chapter 6 will summarize the analytical 
techniques and the limitations of these techniques, in performing a cost-
effectiveness analysis of anastrozole and megestrol acetate therapies. 
Health and economics. 
In western societies, much of the consumption of health resources is that 
which relies on new medical technologies. Economists are advocating the practice 
of evidence based medicine to ensure that the provision of health care and the use 
of new medical technologies is equitable, effective, and efficient. It is imperative 
that effective and economical therapies are promoted in order to ensure the users 
of our health care system receive the best possible medical care for the resources 
consumed. 
Allocative decision making explores ways in which one can analyze the 
costs and the benefits of new medical technologies in order to best govern the 
distribution of scarce resources. Decisions concerning which medical technologies 
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should be supported by our health care system can be evaluated by using 
analytical methods taken from the disciplines of epidemiology, social sciences, 
medicine, economics, and pharmacy. 
The method used to evaluate the clinical and economic value of drugs is 
pharmacoeconomics. Pharmacoeconomics involves the systematic and 
comprehensive analysis of costs and benefits of drug therapies in order to 
understand their impact on the health care system (Bootman, Townsend & 
McGhan, 1996). 
Federal and provincial agencies, hospitals, pharmaceutical manufacturers, 
and universities perform pharmacoeconomic evaluations. A federal agency, the 
Patented Medicine Prices Review Board (PMPRB), uses clinical and economic 
information in order to determine whether drugs coming to market offer 
innovative therapies and whether the cost of those therapies is reasonable. The 
PMPRB uses pharmacoeconomic information to guide the establishment of 
Canada wide drug pricing policies. Drug pricing policies are established so that 
drugs are priced at what is believed to be a fair market value (PMPRB, 1996). 
Provincial Ministries of Health use pharmacoeconomics to determine what 
medications should be available on provincial drug formularies and what 
medications should be available for government reimbursement. In British 
Columbia (B.C.), the Therapeutic Initiative and Pharmacoeconomic Initiative 
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evaluates drugs based on clinical and economic information. The Therapeutic and 
Pharmacoeconomic Initiatives membership is composed of physicians, 
economists, health policy experts, and pharmacists. The recommendations from 
these initiatives are used by the B.C. Ministry of Health to manage the provincial 
drug formulary and establish a reference based drug pricing program. The 
reference based pricing program sets a maximum reimbursable drug price for 
medications that are considered therapeutically equivalent. 
While the Therapeutic and Pharmacoeconomic Initiatives evaluate drugs 
for the B.C. provincial drug formulary, the B.C. Cancer Agency and B.C. 
hospitals do not utilize such initiatives in their formulary review process. The 
B.C. Cancer Agency and B.C. hospitals perform few detailed pharmacoeconomic 
studies as they do not have the resources, or the expertise, that the Therapeutic 
and Pharmacoeconomic Initiatives have. 
Canadian hospitals and cancer agencies also perform pharmacoeconomic 
evaluations. Hospitals and cancer agencies use pharmacoeconomics to measure 
the cost-effectiveness of drug therapies. Hospitals and provincial cancer agencies 
try to support drug therapies which offer clinically significant outcomes at a cost 
that the institutions can afford. Drug therapies that do not offer clinical outcomes 
that are not significantly better or where the costs are not less than other equally 
effective treatments, would not be considered. 
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Although there are numerous groups performing pharrnacoeconomic 
evaluations, it is only recently that methodological guidelines have been 
developed. Analysts and users of pharrnacoeconomic studies need to have a clear 
understanding of the methodological principles behind these evaluations. A clear 
understanding of the methodological principles will ensure that the 
pharrnacoeconomic studies produce reliable and valid information. 
In order to facilitate high quality pharrnacoeconomic studies the Canadian 
Coordinating Office for Health Technology Assessment (CCOHTA) has 
developed pharrnacoeconomic guidelines (CCOHTA, 1997). CCOHTA 
guidelines divide the pharrnacoeconomic evaluation process into: a 
pharmaceutical review of therapy, defining the perspective of the analysis, 
applying a methodology (e.g. cost-effectiveness analysis), identification and 
presentation of costs and consequences, measuring costs and consequences, 
discounting future costs and consequences, performing sensitivity analysis, and 
presenting the analysis. 
Even with high quality data, a pharrnacoeconomic evaluation should only 
be used as an aid in the decision making process. The primary purpose of 
pharrnacoeconomics is to provide the decision maker with clinical and economic 
evidence that describes the outcomes of a particular intervention and how it will 
affect the distribution of resources. Pharrnacoeconomics should not "replace hard 
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thinking, careful consideration, good judgment and common sense" (CCOHT A, 
1994, p. 1). 
Pharroacoeconomics of cancer therapies. 
The screening and the treatment of cancer are under scrutiny by health 
administrators and government bodies because of the large amounts of resources 
that are being consumed. It is estimated that, in industrialized countries, 
expenditures on cancer treatments may account for as much as six percent of the 
gross national product (Jonsson, Clausen & Hansen, 1995). With the increasing 
numbers of elderly, with the growing exposure of the public to carcinogenic 
agents, and with improvements in the diagnostic testing of cancerous tumors, the 
prevalence and the costs of cancer related illnesses will continue to rise (Desch, 
Hillner, Smith & Retchin, 1993). 
Recent attention has focused on how the best possible care can be 
provided to cancer patients while controlling rising costs. Hospitals, governments 
and cancer agencies are each trying to find ways to operate as efficiently as 
possible. Health professionals are being forced to find ways of reducing the 
consumption of scarce resources while still providing quality care. 
While ensuring efficiencies in cancer treatments is paramount, researchers 
are concerned that there are apparent inequities in funding between different types 
of cancer treatments. Jonsson et al. (1995) believe that noncurative cancer 
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treatments are not receiving their fair share of resources. They believe that society 
has an obligation not to consider incurable cancers as a failure and limit its 
funding because of prognosis. They go on to state: 
.. . we would like to point out that economic allocations and the distribution 
of resources in the treatment of cancer must be determined by the possible 
outcome of treatment; however, outcome and cure cannot be equated. We 
would also like to emphasize the conceptual errors that may be introduced 
by interpreting cure as 'success' and lack of cure as ' failure ' , 
interpretations that are too narrow. Stabilisation of incurable cancer for a 
period of time, together with the provision of a good quality of life, can 
itself be considered a satisfactory goal until curative therapy becomes 
available (p. 280). 
Examples of incurable cancers that could receive improved therapies 
include testicular cancer, some hematological cancers, and metastatic breast 
cancer (Jonsson et al., 1995). The treatment ofthese cancers should be evaluated 
in the same way as curable cancers and the allocation of funds should be based on 
sound therapeutic and economic analysis. Pharmacoeconomic evaluations of the 
treatment of incurable cancers that could provide effective cytoreduction therapies 
need to be promoted. 
Given this dilemma of equitable resource allocation and the fact that, when 
working with finite resources, one must concede some health benefits over others, 
determining how to choose where funds should be made available is a difficult 
task. Pharmacoeconomic analysis of cancer therapies should consider measuring 
outcomes that are meaningful to the specific disease states that are being studied. 
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For example, event free or disease free survival in curable cancers maybe a more 
appropriate outcome measure than quality of life. Event free or disease free 
survival is important when cytotoxic treatments in curable cancers are relatively 
short in duration compared to the remaining life years and the possibility of 
success (e.g. , cure) outweighs the negative health effects received from the toxic 
chemotherapy (Jonsson et al. , 1995). 
For incurable cancers, quality of life and life-years gained are the best 
outcome measures for most pharmacoeconomic evaluations. Quality of life is 
important for two reasons. First, research has shown that cancer patients find that 
severe pain and confinement to a bed is regarded as worse than death (Hall & 
Tattersall, 1995). Second, when death is inevitable the toxic effects from the 
treatment may not be worth the gain in survival. Life-years gained would be an 
appropriate outcome measure for incurable cancer drug therapies where patients 
feel the extra time attributed to the treatment outweighs the adverse effects 
(Jonsson et al. , 1995). 
Although certain outcome measures are more applicable to specific types 
of cancers, deciding which measurement to use may not be easy. For example, the 
clinical data needed for the evaluation may not be collected, or the data used in a 
comparative analysis is not sensitive enough to detect differences between the 
treatment states being studied (Drummond, Stoddart & Torrance, 1993). In many 
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pharmacoeconomic evaluations, the outcome measure is quality of life and is 
considered a cost-utility analysis (CUA). A CUA allows the analyst to apply a 
utility score according to the quality of life that the patient experiences. In CUA, 
the outcome measure is expressed as a product of utility and length of survival. In 
its final form, a CUA is defined by the cost per quality adjusted life years (or 
QAL Y) (Bootman et al. , 1996). 
In the present thesis, the outcome measure of life-years gained will be 
used to examine which drug therapy, anastrozole or megestrol acetate, is the more 
cost-effective in treating advanced hormonally responsive breast cancer. 
In cost-effective analysis (CEA), the outcome measure could be any 
clinically significant quantifiable effect that is common to the treatments being 
studied (Bootman et al., 1996). The costs and the effectiveness components are 
evaluated separately and then expressed as a cost-to-effectiveness ratio (e.g. , cost 
per life-years gained). A cost-effectiveness ratio is determined for each treatment 
group and the difference between the two cost-effectiveness ratios is expressed as 
an incremental ratio. The components ofthe cost-effectiveness ratio and the 
specific calculations to arrive at the ratio will be provided later in the paper. 
The survival outcome measure for each treatment group can be determined 
by utilizing clinical data from drug trials and/or from using epidemiological data 
from cancer registries. The basic strategies underlying the analysis include: 
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estimating the survival for each treatment group at specific points in time, 
determining the significance of the survival values, applying the survival rates for 
a hypothetical cohort of patients in each treatment group, running the cohort for a 
specified time, and performing a final count of patients for each group (Lee, 
1980). 
Unfortunately, it is only in the last few years that quality 
pharmacoeconomic studies of cancer therapies have been performed. Many of the 
methods used, such as measuring quality of life and the counting of cancer 
treatment related costs, need further development. Also, while clinical trials of 
cancer therapies provide valuable information regarding tumor cell response or 
time to treatment failure, researchers still have difficulty ascertaining the true 
value of such information (Rubens, 1996). Hopefully, pharmacoeconomic 
analysis of cancer treatments will promote the use of effective therapies and 
ensure that funding priorities are equitable. 
Breast cancer therapies. 
Breast cancer is the most common cancer found in women in Europe and 
North America. The highest incidence rates in the world are in Hawaii, California, 
and British Columbia (Veronesi, Goldhirsch & Y arnold, 1995). In British 
Columbia (B.C.) the estimated age standardized incidence ofbreast cancer is 121 
cases per 100,000 women (National Cancer Institute of Canada, 1996), while in 
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Japan the estimated age standardized incidence is approximately 12 cases per 
100,000 women (Veronsi et al. , 1995). Women with breast cancer usually live 
longer than those with other common types of malignancies, such as lung and 
colorectal cancers. In Canada one in nine women will be diagnosed with breast 
cancer and one in twenty-five will die from the disease (National Cancer Institute 
of Canada, 1996). 
Breast cancer is rare in women less than 30 years of age but, as age 
increases, the incidence rate also increases. Breast cancer usually appears as a 
slow growing painless mass until detected by physical examination or 
mammography. The final diagnosis is made by microscopic examination of the 
breast tissue. Treatment is determined by the extent of the disease and the 
woman' s age. Treatment factors which are to be considered include: "the extent, 
pattern and aggressiveness of the disease, indices of likely hormone sensitivity, 
such as steroid receptor status, and menopausal status" (Rubens, 1996, p. 2). 
When there is no sign of the cancer involving peripheral sites the most common 
treatment is a lumpectomy, modified radical mastectomy, or a total mastectomy. 
After surgical resection further cytoreduction, such as radiation and/or 
chemotherapy, may be performed. 
When the cancer has advanced and spread to the lymph nodes and other 
sites, the disease is said to be metastatic and treatment is considered palliative. 
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Veronesi et al. (1995) recommend that the treatment objective for metastatic 
breast cancer "should be to increase the total duration of time with no or few 
disease related symptoms using the therapy associated with the lowest cost in 
terms of side-effects" (p. 1274). Figure 1 illustrates a schematic for the treatment 
of advanced breast cancer in women. 
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I Aggressive visceral disease I Other metastatic 
I 
I Potentially hormone I 
No Yes 
I 
Premenopausal Postmenopausal 
Ovarian ablation 
LH-RH agonist Tamoxifen 
Tamoxifen 
Response? 
I I 
No Yes 
I 
Progestogens 
Aromatase 
inhibitors 
Cytotoxic chemotherapy 
Fi~ure 1 Treatment of advanced breast cancer. From "Key Issues 
in the Treatment of Advanced Breast Cancer: Expectations and 
Outcomes" by R. Rubens, 1996, Pharmacoeconomics. 9(Suppl. 2), 
p. 3. 
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Women with aggressive metastatic visceral breast cancer require 
chemotherapy to reduce the rapid progression of the disease. For less aggressive 
metastatic breast cancers, treatment is dependent upon whether the tumor' s 
mitogenic activity is sensitive to the presence of estrogen. Women whose breast 
cancer is sensitive to estrogen are considered to have estrogen-positive tumors. 
These women make up the majority of breast cancer patients and have been 
shown to have an improved prognosis compared to women with estrogen-negative 
status (Veronesi et al. , 1995). 
For women with hormone responsive breast cancer, the primary treatment 
is altering the hormonal environment of the tumor. The course of therapy depends 
on menopausal status. Premenopausal women may undergo ovarian ablation or 
drug treatments with luteinizing hormone-releasing hormone (LH-RH) or 
tamoxifen. Postmenopausal women who are estrogen-positive will likely benefit 
from tamoxifen therapy. Tamoxifen competitively forms an estrogen receptor 
complex which blocks the growth stimulatory mechanisms controlled by 
endogenous estrogen. However, for some women, receptor mediated blockade 
will eventually regress and the tumor(s) will grow (Ruben, 1996). 
Women who have responded to tamoxifen therapy and then show signs of 
failure, may experience secondary regressions from additional hormonal 
manipulation. It is postulated that tumor regression is a result of cellular 
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adaptation by the development of estrogen receptor mutations (Santen, 1996). The 
tumor cell may then be able to receive hormonal stimulation by mutating the 
receptor so that treatment with estrogen receptor antagonists (e.g. , tamoxifen) are 
no longer effective. This may help explain why changing from an estrogen 
receptor antagonist, when regression develops, to a medication with a different 
mechanism of action may help delay further disease progression. 
Third generation aromatase inhibitors may help to prolong survival in 
postmenopausal women by inhibiting the biosynthesis of estrogen (Zeneca, 
1997a). Although circulating estrogen concentrations are low in postmenopausal 
women, tumor cells can receive estrogen from the peripheral aromatization from 
fat and muscle tissue and from local aromatization from the tumor (Brodie, 1996). 
Therefore, inhibiting estrogen biosynthesis at the peripheral and local level may 
help to reduce further tumor proliferation. The clinical trials of these third 
generation aromatase inhibitors suggest that they may be useful in first and 
second-line therapy (Smith & Henderson, 1996). 
Due to the high costs associated with treating breast cancer, and the 
clinical uncertainty surrounding the benefits of the new pharmaceutical 
technologies, economic constraints are forcing provincial cancer agencies to limit 
access to third generation aromatase inhibitors. For example, the British Columbia 
Cancer Agency (BCCA) has restricted the use of the new aromatase inhibitor 
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anastrozole to "palliative treatment of hormonally sensitive metastatic breast 
cancer in patients who have progressed after tamoxifen and megestrol acetate 
treatment and have unacceptable side effects from aminoglutethimide" (BCCA, 
1997, p. 1 ). Pharmacoeconomic analysis of third generation aromatase inhibitors 
will help to explore the costs and the effectiveness of this type of new therapy and 
assist provincial cancer agencies and Ministries of Health to decide how these 
new drugs fit into their current cancer treatment policies. 
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Chapter 2 
Pharmacoeconomic Analysis 
This chapter will describe the technical aspects involved in performing a 
pharmacoeconomic analysis. The chapter will discuss the cost-effectiveness ratio 
and the incremental cost-effectiveness ratio. Components that make up these 
ratios will be highlighted. The chapter will describe three clinical decision 
modeling methods for the organization of pharmaceutical data. 
Developim~ the cost-effectiveness analysis. 
The technical aspects involved in the development of a cost-effectiveness 
analysis can be divided into three categories. These are: the development and 
structure of the pharmacoeconomic problem; the assessment of methodological 
assumptions; and the evaluation of costs (Weinstein, 1981 ). 
In the development of the research problem, the pharmacoeconomist needs 
to define the population of interest, the treatment options for the specific disease 
states, the risks and benefits associated with each treatment, and to assess the 
availability of data. The pharmacoeconomist must identify which intervention will 
be the comparator and determine what outcomes will be used to measure the 
drug' s effectiveness. During the structuring phase of the evaluation a decision tree 
model serves as a useful method of structuring and describing the various 
treatment options and their outcomes. 
. 
. ·~ 
. 
••• 
/ 
Cost-Effectiveness Analysis 26 
The second part of a cost-effectiveness analysis is understanding how 
assumptions made during the early stages of the evaluation can affect the results. 
Economists recognize that a comprehensive evaluation of costs and health effects 
often leads to a large number of assumptions being introduced into the study II 
(Weinstein, 1981 ). These assumptions create uncertainties that impact on the 
significance ofthe final results. Testing the significance ofthe assumptions is 
carried by sensitivity analysis. 
Boatman et al. ( 1996) state that "sensitivity analysis is a method of 
determining whether the conclusion of an economic evaluation changes when the 
value of one variable is varied as all other variables are held constant" (p. 70). 
Sensitivity analysis is accomplished by first determining which variables contain 
uncertainty. Those variables with uncertainty are then assessed for the magnitude 
of the uncertainty and the study is re-run with the revised values (Siegel, 
Torrance, Russell, Luce & Weinstein, 1997). The results ofthe re-run study are 
compared to the original to determine whether the uncertainty had any impact on 
the findings. 
The third part of the cost-effectiveness analysis is the measuring and 
reporting of all relevant costs and comparing those costs with the effectiveness 
portion of the analysis. Costs are determined according to the perspective used. 
The perspective is the point of view from which the analyst conducts the 
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evaluation. Pharmacoeconomic perspectives include the societal, the institutional, 
and the patient's. An analysis which uses the societal perspective would consider 
the consumption of resources for all members of society. Institutional and patient 
perspectives are more narrow in the evaluation of costs since they encompass only 
those costs which affect the institution or individual patient. 
Costs can be broken down into direct, indirect and intangible categories. 
Direct costs are those that involve the transfer of money. For example, direct costs 
include capital costs, drug costs, laboratory costs, labor costs, and patient "out of 
pocket" expenses (Drummond, Stoddart & Torrance, 1993). Indirect costs are 
those that do not involve the exchange of money but that affect the use of other 
resources. For example, indirect costs include lost leisure time and time from 
work. Intangible costs are costs where no money is exchanged and the effect on 
the consumption of resources is either difficult to measure or, in dollar terms, is 
unquantifiable. For example, intangible costs include psychological loss and pain 
or suffering. 
In pharmacoeconomic analysis, a comprehensive list of costs is gathered 
for each treatment. Final costs are then tallied and compared to the effectiveness 
of each therapy. The costs and the effectiveness for each treatment are represented 
as a ratio of costs to effectiveness. The cost-effectiveness ratio for this study is 
expressed as costs (in Canadian dollars) versus the effectiveness outcome (e.g. , 
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life years gained). Further economic evaluations may then be performed such as 
the calculation of an incremental cost-effectiveness ratio. 
Components of the cost-effectiveness ratio. 
The components ofthe cost-effectiveness ratio can be expressed as follows 
(Weinstein, 1977, 1980): 
(1) 
where: in the numerator~ c R x is the direct costs of treatment (e.g., drug costs, 
drug administration costs, costs associated with laboratory tests), ~ c s£ is costs 
associated with the drug' s side effects (e.g., nausea, vaginal bleeding), 
and !J. C Mo rh is the savings associated with the prevention of morbid events (e.g., 
brain metastases). In the denominator !J. Y is the change in effectiveness (e.g., 
change in life years), !J. YsE is the adjustment for side effects, !J. Y Mo rh is the 
adjustment for a reduction in morbidity, and !J. Ysymp is the adjustment for the 
relief of symptoms (Weinstein, 1980). 
In Equation 1 the net cost calculated in a cost-effectiveness analysis is 
represented by the numerator and the net effectiveness is determined by the 
denominator. Adjustments in the effectiveness component are determined by the 
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perspective and the methodologies used in the analysis. For example, modifying 
the effectiveness component of the ratio by applying adjustments for side effects, 
morbidity and the relief of symptoms is usually considered a cost-utility analysis. 
Cost-utility analysis allows the researcher to account for less tangible aspects of a 
person' s well being. A person's well being is measured as a utility value. Utility 
values are applied to the effectiveness portion of Equation 1. Some methods used 
to determine utility values are the standard gamble, time trade off, healthy years 
equivalent, and willingness to pay techniques (Bonneterre, Schraub, Lecomte & 
Mercier, 1996). 
CCOHTA (1994) recommends that, once the cost-effectiveness ratio has 
been calculated, the ratios for each drug therapy should be compared and 
expressed in incremental terms. The incremental cost-effectiveness ratio is the 
ratio of the difference between the net costs in the numerator and the difference 
between the net effectiveness in the denominator (Detsky, 1990). The incremental 
cost-effectiveness ratio is expressed in Equation 2. 
(2) 
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where: in the numerator C 1 is the net cost for treatment 1 and C 2 is the net cost 
for treatment 2. In the denominator E 1 is the net effectiveness for treatment 1 and 
E 2 is the net effectiveness for treatment 2. 
The incremental cost-effectiveness ratio provides valuable information as 
it "reveals the cost per unit of benefit of switching from one treatment strategy 
(usually already in operation) to a new strategy" (Detsky, 1990, p. 151). For 
example, the cost-effectiveness ratio for drug A is $1 ,800 per 2.2 years of life, and 
for drug B is $1 ,500 per 1. 9 years of life. The incremental ratio is calculated as 
follows: 
c $1,800-$1,500 
Incremental-= = $1 ,000 per life year gained (3) 
E 2.2years- 1.9years 
Since drug A costs $1,000 for each life-year gained over drug B, Drug B is more 
cost-effective. 
Modelin2 and decision trees. 
The most difficult aspect of carrying out a pharmacoeconomic analysis is 
first determining what information is required and second deciding how to 
organize the clinical and economic data. Pharmacoeconomic information will 
need to be structured into an analytical framework that will break the evaluation 
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into manageable units. The manageable units will first need to be defined, 
organized, and then presented in a comprehensive format. 
Decision models are useful analytical tools for structuring a 
pharmacoeconomic evaluation. Decision models organize clinical and economic 
information into "its component parts so that they can be analyzed individually 
and then recombined in a systematic way" (Weinstein, Fineberg et al., 1980, p. 4). 
Decision trees, recursive decision trees, and Markov models are types of decision 
models used in structuring clinical and economic information. Decision models 
are used not only for systematically organizing pertinent data into a structured 
framework, but they can also assist in determining the likelihood of various 
treatment events occurring. 
The decision tree is an analytic tool that tracks the options and the 
outcomes for each treatment group at a particular point in time. The decision tree 
contains decision nodes, chance nodes and treatment paths. The tree is structured 
from left to right starting with a decision node. The timing of the nodes and the 
paths which connect the nodes, correspond to the clinical course of the event 
(Weinstein, Fineberg et al., 1980). 
Figure 2 illustrates a branch of a decision tree for the treatment of a patient 
with acute abdominal pain. Decision nodes are points where alternative actions 
are selected and are represented as squares. The first square in Figure 2 is a point 
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where a physician must decide to intervene immediately or wait six hours and 
monitor the patient's abdominal pain. The second square is a point where the 
physician must decide whether or not to operate. The lines connecting the first 
two decision nodes are treatment paths. 
Survive Survival 
Perforated 
Die Death 
Operate Inflamed 
Survive Survival 
Die Death 
NSAP 
Survive Survival 
Die 
Death 
Decide Now 
Survive Survival 
Perforated 
Die Death 
Die Death 
Survive 
Inflamed 
Survival 
Do Not Operate 
Survive 
NSAP 'Wait Six Hours Die 
Death 
Figure 2. A decision tree branch for the treatment of a patient with acute 
abdominal pain. NSAP refers to nonspecific abdominal pain. From Clinical 
Decision Analysis (p. 15) by M. C. Weinstein, Fineberg et al. , 1980, Toronto: W. 
B. Saunders Company. 
Chance nodes are points where "one of several possible events beyond the 
control of the decision maker may take place. It is represented in a decision tree as 
a small circle" (Weinstein, Fineberg et al, 1980, p. 14). As shown in Figure 2, 
following the decision of whether or not to operate, the possible events are either 
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a perforated appendix, an inflamed appendix, or nonspecific abdominal pain 
(NSAP). Consequences of the three chance nodes branch out to two other chance 
nodes. Those chance nodes are survival and death. 
A recursive decision tree is similar to a standard decision tree in that it 
outlines the events and outcomes in a systematic diagram. However, a recursive 
decision tree also provides a means of identifying events that are repeated 
throughout the clinical course. By including repeated events in the recursive tree 
the clinical problem can structured according to the time intervals (e.g., a month, 
or a year) at which these events occur. The cycling of the repeated events in a 
recursive decision tree helps to track their reoccurrence at various points in time. 
Figure 3 shows a recursive decision tree. The chance events from 
anticoagulant therapy are represented by the first three nodes as bleed, embolus 
and no event. Bleed and embolus events can be fatal or non-fatal. Since bleed, 
embolus and no event may occur more than once, the tree structure repeats itself. 
Period 1 and Period 2 contain the same events in the same order but occur in a 
different time frame. However, complex analytical problems that are structured 
into a decision tree can become too large and impractical for modeling purposes. 
For example, Figure 3 would become too confusing if it extended past period 2. 
~---
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Figure 3. A recursive decision tree of anticoagulant therapy. Period 1 and period 2 
is comprised of a main branch starting with bleed, embolus, and no event. From 
"Markov Models in Medical Decision Making: A Practical Guide," by F. A. 
Sonnenberg and J. R. Beck, 1994, Medical Decision Makin~, 13, p. 324. 
Another way of structuring repeated health events is by using a Markov 
model (Briggs & Sculpher, 1997). The Markov model is similar to a recursive 
decision tree in that it structures events in chronological order and provides a 
means of documenting the cycling between repetitive events. The Markov model, 
however, limits the number of health states to only three or four events. More than 
four events would make the model cluttered and confusing. 
·~ 
'~----------------------------------------------------------------------~ 
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Pauker and Kassirer (1987) describe a Markov model as a small set of 
health states with transitions between the states. The likelihood of changing from 
one health state to another is called transition probability. Figure 4 illustrates a 
"three-state Markov Model" where patients reside in any one ofthe three states 
and change to other states at different points in time (Beck & Pauker, 1983, p. 
421). 
Figure 4. A three state Markov model illustrating transitional probabilities from 
time ito i+ 1 for the health states well, ill, and dead. From "The Markov Process in 
Medical Prognosis" by, J. R. Beck and S. G. Pauker, 1983, Medical Decision 
Makin2. 3(4), p. 421. 
The three health states are well, ill, and dead. The model allows the 
patients to be in any one of the three states depending on whether their clinical 
problem requires them to be in that state (Beck & Pauker, 1983). The patients 
distribute to other health states according to the transition probabilities after a 
fixed amount of time. The transition probabilities are shown adjacent to the lines 
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flowing from one state to another. For example, the transition probability from the 
well state at time i, to the health state ill at time i+ 1, is designated as Pwi. 
Whatever decision model that is used, the most effective method will 
incorporate all significant clinical events into a structured tool. Choosing the 
correct model, and the information to include in the model, should be based on a 
thorough understanding of the events and outcomes in each treatment group. 
Knowing how those events and outcomes occur over time, and which events and 
outcomes are clinically and economically significant, will provide the researcher 
with an understanding as to which model would be best suited to the 
pharmacoeconomic evaluation. 
Once event or transitional probabilities are determined, a cohort 
simulation of a defined number of patients can be performed on the decision 
model. If the model is time dependent, such as with a recursive decision tree or 
Markov model, the patients would be distributed among the various events or 
health states after a set period of time (Sonnenberg & Beck, 1993). The simulation 
would be run until the time horizon is completed. The results of a simulation of a 
cohort can be tabulated and compared to the cost data. 
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Chapter 3 
Clinical Data 
There are many possible sources of clinical data for use in a 
pharmacoeconomic evaluation. Clinical data comes from randomized clinical 
trials, retrospective drug information from various databases, epidemiological data 
from the literature or databases, or from professional organizations or agencies. 
The primary source of clinical data for the anastrozole/megestrol acetate example 
used in this thesis could come from randomized clinical trials. This chapter will 
review the anastrozole/megestrol acetate randomized clinical trial data and how it 
would be used in a pharmacoeconomic evaluation. Although actual clinical data 
will be utilized in this chapter, hypothetical values will be used in later chapters 
for describing pharmacoeconomic calculations and tables. 
Pharmacoeconomics and the randomized clinical trial. 
A pharmacoeconomic evaluation relies on interpreting and extrapolating 
results from randomized clinical trials (RCTs). A RCT is required to demonstrate 
the safety and efficacy of new drugs. A RCT also provides a means of comparing 
new drug treatments to existing therapies. Drug therapies which have 
demonstrated at least an incremental advantage over existing therapies "usually 
require randomized comparison trials to demonstrate convincingly statistically 
significant improvement[s]" (Kaufman, 1993, p. 2801). The steps involved in 
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performing a RCT are: assignment of participants into treatment groups, 
assessment for defined endpoints or outcomes, analysis of the results, and 
interpretation of the findings (Riegelman & Hirsch, 1989). A RCT that has been 
carefully designed and has demonstrated a significant improvement in drug 
therapy is the basis for undertaking a pharmacoeconomic analysis since it is the 
source of data for the effectiveness data that is required. 
Many of the recent advances in the treatment of progressive breast cancer 
have come from RCT data which have helped to identify safe and effective 
therapies (Kaufman, 1993). While RCTs have been "capable of identifying 
effective new therapies and eliminating ineffective, unnecessary, or harmful 
therapies," pharmacoeconomic evaluations have not kept pace with recent RCT 
information (Kaufman, 1993, p. 2801). 
An overview of anastrozole and me2estrol acetate randomized clinical 
In order to determine whether a pharmacoeconomic analysis is justified, a 
close evaluation of the clinical findings is necessary. The assessment of the RCT 
data should consider the strengths and weaknesses of the findings and should 
consider that clinical trial data may not reflect real-life drug utilization patterns 
(Clemens et al. , 1995). Clemens et al. comment on the problems of applying RCT 
data to pharmacoeconomic evaluations. 
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Clinical trials are the primary source for efficacy data at approval. Clinical 
trials will generally be powered based on the primary clinical endpoint(s). 
Such trials may be under-powered for secondary end-points including 
resource use and cost data (p. 172). 
Table 1 shows drug tolerability results from the RCT data for anastrozole 
and megestrol acetate (Zeneca, 1997b ). 
Table 1 
The Incidence of Adverse Effects for Anastrozole and Me2estrol Acetate 
Adverse Event Group Anastrozole Anastrozole Megestrol acetate 
1-mg od (n=262) I 0-mg od (n=246) 40-mg qid (n=253) 
n % n % n % 
Gastrointestinal Disturbance 77 (29.4) 81 (32.9) 54 (21.3) 
(nausea, vomiting, diarrhea) 
Hot Flushes 33 (12.6) 29 ( 11.8) 35 (13 .8) 
Edema 19 (7.3) 28 (11.4) 35 (13.8) 
Thromboembolic Disease 9 (3.4) 4 (1.6) 12 (4.7) 
Vaginal Dryness 5 (1.9) 3 (1.2) 2 (0.8) 
Weight Gain 4 (1.5) 10 (4.1) 30 (11.9) 
~ From "Arimidex: a Significant Advantage in the Only Reliable Parameter -
Survival," by Zeneca, 1997, Product Information Leaflet, Zeneca Pharma, 
Ontario. 
The table shows that, overall, the number and types of adverse effects are 
similar for both drugs. There are, however, a few significant differences. In the 
anastrozole 1 0-mg group, women experienced greater gastrointestinal effects than 
the megestrol acetate group. However, in the megesterol acetate 40-mg qid group, 
women experienced greater weight gain than both of the anastrozole groups 
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(Budzar et al, 1996). Zeneca (1997a) reported that the megestrol acetate group had 
a greater number of participants who withdrew from the study for intolerable 
adverse effects than either of the anastrozole groups. The withdrawal rates due to 
adverse effects for the megestrol acetate 40-mg qid group was 4.0 percent, in the 
anastrozole 1-mg od group 2.7 percent, and in the anastrozole 10-mg od group 3.3 
percent. However, there were no statistically significant differences in withdrawal 
rates between the three treatments (Budzar et al., 1996). 
Critical appraisal and further analysis of the clinical data should be 
considered before proceeding with a pharmacoeconomic evaluation. It would be 
disheartening to find that the work of performing a pharmacoeconomic evaluation 
was wasted because the results reported were based on invalid RCT data or the 
new treatment offered no additional clinical benefit. For example, in the 
anastrozole 1-mg and 1 0-mg daily ( od) and megestrol acetate 40-mg four times 
daily ( qid) comparisons the phase III survival data indicates that the anastrozole 
1 0-mg od treatment is less effective than the anastrozole 1-mg od treatment and 
also exhibits a greater number of adverse effects. A pharmacoeconomic evaluation 
of anastrozole 1 0-mg od is therefore not worth pursuing. 
The RCT data presented by Zeneca suggested that anastrozole "is well 
tolerated and as effective as megestrol acetate for the treatment of postmenopausal 
women with advanced breast cancer" (Budzar et al. , 1996, p. 2000). But before 
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proceeding with the pharmacoeconomic analysis a review of the findings is 
needed. 
Table 2 highlights the survival differences for the anastrozole and 
megestrol acetate treatments after the median 31 month follow-up period. 
Table 2 
Summary of Survival Information for Anastrozole and Me~estrol Acetate from 
Clinical Trials 0004 and 0005 
Phase III Trial Number Anastrozole Anastrozole Megestrol acetate 
1-mg od 10-mg od 40-mg qid 
0004 
Number of patients who died(%) 66 of 128 81 of 130 79 of 128 
(51.6) (62.3) (61. 7) 
2-year survival rate 62.0% 58.0% 53.1% 
Median time to death (months) 29.6 25 .7 26.7 
0005 
Number of patients who died(%) 85 of 135 70 of 118 92 of 125 
(63.0) (59.3) (73.6) 
2-year survival rate 50.5% 50.8% 39.1% 
Median time to death (months) 24.3 24.8 19.8 
0004 & 0005 Combined 
Number of patients who died(%) 151 of263 151 of248 171 of253 
(57.4) (60.9) (67.6) 
2-year survival rate 56.1% 54.6% 46.3% 
Median time to death (months) 26.7 25.5 22.5 
Note. Phase Ill refers to a stage of clinical research where large numbers of 
human subjects are given new medications in order to evaluate their safety and 
efficacy. From "Arimidex: a Significant Advantage in the Only Reliable 
Parameter- Survival," by Zeneca, 1997, Product Information Leaflet, Zeneca 
Pharma, Ontario. 
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A total of 764 women were randomized into the study, 386 women in the 
North American trial (Canada and USA, trial number 0004), and 378 in the 
European trial (Europe, Australia and South Africa, trial number 0005) (Zeneca, 
1997a). Women were randomized into one ofthe three treatment groups: 
anastrozole 1-mg daily, anastrozole 1 0-mg od, or megestrol acetate 40-mg four 
times daily. Women were routinely assessed by physical examination, by bone 
scans, and by radiographic examinations. Women were withdrawn from the trial if 
they experienced serious adverse effects, unwilling or noncompliant with 
procedures, or were found to have significant cancer progression (Budzar et al. , 
1996). Screening, drug tolerability and efficacy assessments were performed on a 
routine basis. Efficacy assessments included: time to treatment failure, tumor 
response, response duration-and time to death (Zeneca, 1997a, Budzar et al. , 
1996). 
The median time to death for anastrozole 1-mg od, anastrozole 1 0-mg od 
and megestrol acetate 40-mg qid was reported to be 26.7, 25.5 and 22.5 months 
respectively. The two year survival rate for anastrozole 1-mg od, anastrozole 10-
mg od and megestrol acetate 40-mg qid was reported to be 56.4, 54.6 and 46.3 
percent respectively. The results indicate that the anastrozole 1-mg od group had a 
median survival advantage of 4.2 months and 3.0 months over the anastrozole 10-
mg od and megestrol acetate 40-mg qid groups respectively. The anastrozole 1-
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mg od group was found to have a two year survival advantage of9.8 and 1.5 
percent over the anastrozole 1 0-mg od and the megestrol acetate 40-mg qid 
groups respectively. 
Since RCT findings are reported in numerous ways, researchers are 
recommending that clinical trial information should be presented in a less 
confusing and a more standardized format (Laupacis, Naylor & Sackett, 1992, 
Therapeutics Initiative, 1996). Laupacis et al. (1992) suggest that "for clinical 
trials, a complementary and simple way to represent the difference between 2 
groups emphasizes the clinical effect of the treatment being studied" (p. 12). They 
state that "the number needed to treat is a useful method of expressing the efficacy 
of a therapy because it incorporates the baseline risk in untreated patients, is easily 
calculated (the inverse ofthe absolute risk reduction), and allows an estimate of 
the effort and cost associated with the therapy" (pp. 13-14). Clinicians who use 
RCT findings that have been reported in terms of relative risk reductions have 
been described as being less critical about the results than if they were reported as 
absolute risk reductions or number needed to treat (Therapeutics Initiative, 1996). 
In the anastrozole versus megestrol acetate case, the absolute risk reduction 
is calculated by taking the percent mortality rate for the megestrol acetate 40-mg 
qid group minus the percent mortality rate for the anastrozole 1-mg od group. The 
absolute risk reduction for women taking anastrozole 1-mg od for a median time 
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the 31 months was found to be 10.2 percent. This means that 1 0.2 percent fewer 
deaths were found to occur with the anastrozole 1-mg od group over the 31 month 
treatment period than with the megestrol acetate 40-mg qid group. The number 
needed to treat was found to be 10, which indicates that if 10 women were treated 
with anastrozole 1-mg od for a median duration of 31 months, instead of with 
megestrol acetate 40-mg qid, one death would be prevented. Table 3 outlines these 
findings . 
Table 3 
Analysis of Clinical Trials 0004 and 0005 Mortality Data for Anastrozole and 
Me~estrol Acetate 
Megestrol acetate 40-mg qid Anastrozole 1-mg od Absolute Risk Number Needed 
# of patients # of patients Reduction to Treat 
Total Death Total Death 
253 171 263 151 67.6%- 57.4% = 100/10.2 = 10 
(67.6%) (57.4%) 10.2% 
The phase III efficacy data, and the numbers needed to treat results, indicate 
that a 31 month median treatment with anastrozole 1-mg od demonstrates a survival 
advantage over that of the megestrol therapy. Although the RCT efficacy data 
"refers to the performance of a drug under highly controlled circumstances," a cost-
effectiveness analysis ofthese two drug therapies is worth considering (CCOHTA, 
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1997, p. 20). However, it is important to recognize that the findings cannot be 
reliably extrapolated beyond the 31 month median follow-up period. 
Chapter 4 
Developin2 the Pharmacoeconomic Analysis 
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This chapter will discuss the study population and the time horizon for the 
pharmacoeconomic evaluation. Since CCOHT A recommends that a societal 
perspective should be used whenever an economic analysis is performed, the 
anastrozole/megesterol acetate example will be based on that perspective. Using 
the societal perspective ensures that all clinical and economic outcomes that have 
an impact on the study will be accounted for. Methods for determining the costs to 
the individual patient, the family, the hospital or agency caring for the patient, and 
to the government will be reviewed. A hypothetical list of direct and indirect 
costs, for developing the anastrozole/megestrol acetate evaluation, will also be 
discussed. Actual costs will not be gathered and so hypothetical values will be 
used for calculation purposes. 
Study population. 
In this example, the study population will be defined as comprising 
women with postmenopausal estrogen receptor positive breast cancer, whose 
disease has progressed while on tamoxifen and have switched therapy to either 
anastrozole 1-mg od or megestrol acetate 40-mg qid. 
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Method of evaluation. 
The method of evaluation will be a cost-effective analysis. The 
effectiveness portion of the evaluation will consider the differences in survival 
between the two treatment groups. A cost-effectiveness ratio will be calculated 
from hypothetical cost and survival data and will be expressed as costs versus life 
years (time from start of therapy to death). An incremental cost-effectiveness ratio 
will also be described by using the cost-effectiveness information from each 
cohort. The incremental cost-effectiveness ratio will describe the cost per life-year 
gained for one cohort relative to another. 
The multicentered, randomized anastrozole and megestrol acetate phase III 
trials, and the follow-up period information, will be used as the primary data 
source (Budzar et al. , 1996, Zeneca, 1997a). Although Zeneca' s clinical trial data 
contains time to disease progression, best tumor response, duration of response 
and duration of stable disease, only survival (i.e., time to death) will be included 
in the model. Extracting the retrospective data into the evaluation can be 
problematic and so limitations in the anastrozole and megestrol acetate data will 
be highlighted. Since phase III RCT data measures the efficacy of the treatments 
and not effectiveness, all assumptions made should "be explicitly and thoroughly 
tested with sensitivity analysis" (CCOHTA, 1997, p. 20). 
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Other sources of data could include: drug prescribing rates, clinic and drug 
costs, and epidemiological information from the British Columbia Cancer 
Agency; cost information from the Ministry of Health; drug prescribing and cost 
information from British Columbia Pharmacare; clinical and drug cost 
information from local hospitals; epidemiological information from Vital 
Statistics; and information from literature sources. The specific requirements for 
the types of data will become more apparent as the analysis progresses. 
Time horizon. 
When analyzing survival data, the most appropriate time horizon is to run 
the study until all the participants have died (Lee, 1980). In the 31 month median 
period approximately sixty-two percent of the women participants died. Most 
pharmaceutical company sponsored RCTs are run for the shortest possible 
duration while still being able to demonstrate statistically significant outcomes. In 
order to meet CCOHT A recommendations the time horizon should be extended 
"far enough into the future to capture the major clinical and economic outcomes 
related to the treatment under study" (CCOHTA, 1997, p. 18). 
Since the ideal time horizon should be greater, modeling techniques are 
required to make up the missing data. It is important that modeled data be 
considered since the survival benefit for either anastrozole and megestrol acetate 
at greater than 31 months is unknown. If the clinical trial cannot be run until all 
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patients are absorbed then there should be good clinical evidence to support a 
shorter period. 
In order to determine the time horizon for the modeled data, a review of 
other clinical data for hormonal therapy of progressive breast cancer is needed. 
The long term data from the National Surgical Adjuvant Breast and Bowel Project 
have shown that pre and post-menopausal women, with or without estrogen 
receptor positive breast cancer, receive significant benefit from taking tamoxifen 
for up to five years (Frankel, 1995). Treatment with tamoxifen greater than five 
years has be shown to provide no additional efficacy (Frankel, 1995). Applying a 
similar five year time horizon for this economic evaluation seems appropriate 
since treatment with the first line therapy has been demonstrated to be effective 
for a maximum of five years. 
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Chapter 5 
Quality of Life and Survival 
Most clinicians consider quality of life, or survival, as the most important 
criteria for evaluating cancer treatments. Although many cost-effectiveness 
analyses study both quality of life and survival together, in this evaluation only 
survival will be reviewed. Determining whether to include quality of life in a cost-
effectiveness analysis of cancer therapies should be based on how much impact 
the treatment affects the patient's quality of life and whether the data is available. 
Quality of life was not considered in this evaluation for two reasons. First, 
since treatment with hormonal therapy for progressive breast cancer results in 
fewer side effects than with cytotoxic chemotherapy, the effect on quality of life 
would be significantly less than other more toxic therapies. Most evaluations that 
have included quality of life have been for surgical or cytotoxic therapies where 
the intervention have a significant impact on a person' s well being. Second, 
although quality of life data was gathered during the phase III trials, the 
information was not published by Zeneca due to inconsistencies in data collection. 
In order to develop a better understanding of how anastrozole 1-mg od and 
megestrol acetate 40-mg qid impacts on survival, this chapter will examine 
concepts and methods used in survival analysis. This chapter will also review how 
participants of clinical trials are followed, what the identifiable starting point of 
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treatment is, how losses to follow-up affect the findings, and what methods are 
used to organize and interpret the survival results. 
Survival analysis. 
In Zeneca's phase III trials, women were entered into the study based on 
specific criteria: menopausal status, current medical status (e.g., other illnesses), 
type of breast cancer, and their current medical treatments. Once women met the 
selection criteria, they were then randomized into one of the three groups (i.e. 
anastrozole 1-mg od, anastrozole 1 0-mg od, and megestrol acetate 40-mg qid). 
The date of randomization was used as the start date for treatment and was 
the point from which the duration of therapy was measured. The participants were 
followed until the end of the study or until loss to follow-up. The participants of 
the study may die before the end of the study, some may withdraw early, and 
some may be alive at the end of the trial (Lee, 1980). 
The timing of the various events is central to the analysis of survival. 
Figure 5 illustrates how timing of crucial events and the censoring of data can 
occur in trials where survival is evaluated. Twelve fictitious subjects, identified as 
A through L, in a 36 month study are shown on they-axis of Figure 5. Subjects 
who relapsed or died, are labeled with a R at the time of relapse. Subjects labeled 
withaL were lost to follow-up during the study. Subjects labeled with C were 
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censored. Censored subjects are those who where still alive at the time the study 
ended. 
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B -----------------------------------R 
c R 
0 ---------------------------------4C 
E L 
F R: 
G ----~----------------------_,c 
H R 
: L 
J R 
K --------~----~----_,c 
L L 
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Calendar Month 
Fi~ure 5. Time lines for twelve fictitious study participants. Participant's time 
lines ending with R died at that point in their treatment. Participant's time lines 
ending with L where lost during the study and those ending with C where alive at 
the end ofthe 36 months. From "'Stayin Alive': An Introduction to Survival 
Analysis" by, D. L. Streiner, 1995, Can. J. Psychiatry. 40, p. 439-444. 
Figure 5 illustrates the problems with presenting the data as median 
survival time or relapse rate. Based on the figure, median survival time is 
determined from the study population of only those individuals who died during 
the trial period. For example, only the patients A, B, C, F, Hand J would be used 
in calculating the median survival time (Streiner, 1995). Censored patients would 
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not be included. By excluding censored data the analyst would miss important 
information of who did not die and who dropped out of the trial. 
Without examining the reason for assigning a patient to the censored 
category, the pharmacoeconomist may not be aware that the loss to follow-up 
could be related to the treatment the participants received. If the loss of follow-up 
was related to the treatment then the study would be underestimating the risk of 
therapy (Streiner, 1995). By not including censored participants, the median 
survival time calculation underestimates the benefit accruing to those who are 
most successful in their treatment (Luke, 1993). 
Unfortunately, Zeneca's clinical trial data does not comment on patients 
who were lost to follow-up or who lived beyond the follow-up period (Budzar et 
al., 1996; Zeneca, 1997a). This is a concern since forty percent of the population 
were still alive at the end of the study. Since the number of participants lost to 
follow-up is also unknown the exact survival time cannot be determined. Unless 
there is more information regarding the censoring of data the pharmacoeconomist 
cannot be certain about the reliability of the results. Analysts need to ensure that 
survival probabilities are an accurate representation of all of the clinical data. 
Using relapse rate as a measure of the efficacy can also be problematic. As 
with using median survival times, relapse rates do not take into account 
participants who were lost to follow-up or who were still alive at the end of the 
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study period. In order to accurately evaluate the survival data the 
pharmacoeconomist needs access to the "raw" RCT data. Raw data should contain 
basic information for each participant. The information should include the date of 
randomization, the participants' randomized treatment group, the date of death, 
and the date of loss to follow-up if it occurred. Information as to the reasons for 
loss to follow-up should also be obtained. Once this information has been 
gathered the analyst can then interpret the data by running it through one of the 
many computer programs that analyze survival information, or the analyst may 
organize the data into a statistical table and plot a survival curve. Unfortunately, 
the raw survival data was not available from Zeneca and therefore a thorough 
analysis of survival could not be performed. 
Constructin2 survival curves. 
There are two methods for constructing survival curves. The first method 
is called the product-limit method and is also known as the Kaplan Meier method. 
The product limit method is useful when the study population is less than 1 00 and 
the exact date ofthe event (e.g., death) being monitored is known (Lee, 1980). 
The analyst plots the exact point in time each participant died (Kaplan & Meier, 
1958). The resulting curve "is simply the proportion surviving at various points in 
time" (Coldman & Elwood, 1979; p. 1 065). 
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Figure 6 shows the Kaplan Meier survival curves for the anastrozole 1-mg 
od and megestrol acetate 40-mg qid therapies (Pritchard, 1997). The curves 
represent the overall survival data from the two clinical trials number 0004 and 
0005 . Time zero represents the point at which the women where randomized. As 
time increases along the x-axis the percentage of women surviving decreases. The 
curves provide a graphical representation of the survival data and help to depict 
the differences in survival between the two types of treatments. 
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Fi~ure 6. Survival curves from combined trials 0004 and 0005 . From "Arimidex: 
A Significant Advantage in the Only Reliable Parameter - Survival" by, Zeneca, 
1997, Product Information Leaflet, Zeneca Pharma, Ontario. 
Another method of evaluating raw survival data is by using a life table. 
The life table method is useful when the time of an event (e.g. , death) cannot be 
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accurately determined. The life table method is also useful when the study 
population is large (e.g., greater than 1 00) or when modeled data is required. 
Since the time horizon for Zeneca's randomized clinical trial should be extended, 
a life table method would be useful in producing the modeled data (Lee, 1980). 
A sample of a life table is shown in Table 4. 
Table 4 
Life Iabl~ Qf 12 FictitiQys Parti!;;ipants 
Interval Number Number Number lost Hazard Proportion Cumulative Probability 
(months in at risk died to follow-up surviving proportion density 
the study) surviving function 
0-6 12 I 0 0.0833 0.9167 0.9167 0.0764 
6-12 11 0 2 0.0000 1.0000 0.9167 0.0000 
12-18 9 2 0.2353 0.7647 0.7010 0.1649 
18-24 6 2 0.3636 0.6364 0.4461 0.1622 
24-30 3 0 0.0000 1.0000 0.4461 0.0000 
30-36 2 0.6667 0.3333 0.1487 0.0991 
NQte. From "'Stayin Alive': An Introduction to Survival Analysis" by, D. L. 
Streiner, 1995, Can. J. Psychiatry. 40, p. 441. 
Table 4 represents the data from the fictitious study of 12 people 
previously shown in Figure 5 (Streiner, 1995). The life table contains the number 
of participants at risk, the number who died, the number lost to follow-up, the 
hazard (the proportion of participants at risk of dying during a specific interval), 
the proportion of participants surviving, the cumulative proportion of participants 
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surviving, and the probability density function (probability of a participant dying 
in a specific time interval). 
The hazard ratio, shown in the fifth column of the table, is a useful statistic 
for comparing the survival experiences of two or more treatment groups. Unlike 
survival rate or median survival time, the hazard ratio incorporates all of the 
participant data whether censored or not (Mathews & Farewell, 1985). A hazard 
ratio is calculated from data over time and, unlike other descriptive survival 
statistics, reflects the whole treatment period. A hazard ratio of 0.5 indicates that 
the risk of death is one-half the hazard ratio of 1.0. A hazard ratio of 1.0 indicates 
there is neither an increased nor decreased risk of death. A hazard ratio of 1.5 
suggests a 50 percent increase in risk (Pritchard, 1997).The hazard ratio is 
calculated according to equation (4) as follows: 
Hazard= #ofpeople who died during the interval 
# at risk _ # lost during follow_~ U_E_ 
2 
(4) 
For example, the hazard ratio for the 18 to 24 month interval would be calculated 
as: 
2 
Hazard= --:-
1 
= 0.3636 
6 -
(5) 
2 
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The proportion of participants at risk of dying for the 18 to 24 month interval is 
0.3636, or 36 percent. The only interval with a greater hazard ratio is the 30 to 36 
month interval (i.e. , hazard ratio is 0.6667). 
The hazard ratio accounts for participants who were lost during the follow-
up by assuming that the participants lost were at risk for one-half the interval. 
This is why in equations 4 and 5 the number lost to follow-up is divided by two 
(Streiner, 1995; Lee, 1980). The proportion of participants surviving is equal to 
one minus the hazard ratio. The cumulative proportion of participants surviving in 
the first interval is the proportion of participants surviving in the first interval 
multiplied by one. The cumulative proportion of participants surviving in the 
second interval is the proportion of participants surviving in the second interval 
multiplied by the cumulative proportion of participants surviving in the first 
interval, and so on for the remainder of the table (Streiner, 1995). The probability 
density function is the hazard ratio multiplied by the cumulative proportion of 
participants surviving for each interval. 
The cumulative proportion of participants surviving is also known as the 
survival function and when plotted against time is known as the survival curve 
(see Figure 7 for the survival curve of the data represented in Table 4). Plots of 
the hazard ratios and the probability density functions can also be graphed against 
time. These two types of graphs help the analyst understand how the study 
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population's risk of dying during a particular treatment varies over time. For most 
treatments, where survival is the outcome being measured, the risk of death will 
increase and decrease over the treatment period (Lee, 1980). Understanding how 
the risk of death changes over time provides the analyst with additional 
information as to the treatment's effectiveness. 
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Fi~ure 7. Survival curve for 12 fictitious participants. From '"Stayin Alive': An 
Introduction to Survival Analysis" by, D. L. Streiner, 1995, Can. J. Psychiatry. 
40, p. 442. 
Modeled data. 
Extending the survival curve past the available data can be accomplished 
by using analytical modeling procedures (CCOHTA, 1997). Estimating future 
data points on the survival curve can be carried out by using the survivorship, 
probability density, and hazard function information. This information provides 
the pharmacoeconomist with an understanding of which analytical model would 
I 
il 
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best estimate the survival distribution. The analyst would choose the model 
according to a detailed understanding of the data or by fitting the model to the 
survival, hazard or density curves (Gehan, 1975). The validity ofthe model is 
checked by testing the goodness of fit between the model and the curves. 
Choosing and testing an analytical model is beyond the scope of this paper. The 
reader will find Lee (1980), Gehan (1975), and Buyse et al (1984) are key 
references for creating and handling modeled data. 
Evaluatin2 survival curves. 
The analyst should also be aware of the shapes of survival curves and the 
information they provide. Figure 8 shows three different curves. 
100 (a) 
Years 
Fi2ure 8. Comparing three sets of survival curves for treatment A and B. From 
"Cancer clinical trials: methods and practice," by M. E. Buyse, M. J. Staquet, and 
R. J. Sylvester, 1984, Toronto, Oxford University Press, p. 383 . 
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The survival curves of anastrozole 1-mg od and megestrol acetate 40-mg 
qid therapies shown in Figure 6 are similar in appearance to curve (a) as the 
anastrozole 1-mg od curve lies above the megesterol acetate curve and separates 
as time increases. The anastrozole and the megestrol acetate curves are different to 
curve (a) as they have less separation and that the percentage of participants 
surviving does not reach zero. Curve (a) indicates that treatment A is uniformly 
superior to treatment B over the entire life of the participant. In curve (b) death 
occurs more quickly than with treatment B, but the long term use of either 
treatment results in the same proportion of people dying. Since the proportion of 
participants surviving greater than three years is unknown in the 
anastrozole/megestrol acetate case, the pharmacoeconomist cannot be certain 
whether the anastrozole curve will not follow the same shape as curve (b) or curve 
(c). Curve (c) indicates that treatment A is initially superior to treatment B, but 
treatment B is more superior over the long term than treatment A. Being aware of 
the potential long term consequences of these types of drug therapies is important 
to consider when evaluating their effectiveness. 
Not only do survival curves provide a useful graphical representation of 
the data but they can also be used to estimate the proportion of participants 
surviving. Knowing the proportion of people surviving is valuable information. 
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Survival probabilities at various points in time can be estimated and used in the 
decision model. The probability information would be used to describe specific 
survival outcomes for the treatments under investigation. 
Estimating the proportion of participants surviving can be extrapolated 
directly from the survival curve. Determining survival probabilities from 
extrapolating the data from a curve brings with it considerable error or 
uncertainty. Buyse et al. estimate that, when using survival curves to determine 
the proportion of participants surviving, the "range in error of the curve at a given 
time is roughly± 1/..J (N) , where N'is the number of participants who have either 
already died or are followed up to that time" (Buyse et al., 1984, p. 368). A two 
year survival rate for megestrol acetate extrapolated from the survival curve 
would be approximately 46%. Using the above equation:± li..J253 = ± 0.06, the 
true survival rate would be somewhere between 40 and 52%. 
A z;-test allows the analyst to compare the probability of survival for two 
treatments at a single point in time. The analyst would be able to use the survival 
data already gathered in the life table to determine whether there is a significant 
difference in survival between the two therapies. The z-test equation is as follows 
(Streiner, 1995, p. 442): 
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z = (6) 
The cumulative proportion surviving at a specific point in time for the two 
treatments are P 1 and P2 (this data is already collected in the life table). The 
standard error (SE) for treatment number one is (Streiner, 1995, p. 442): 
= p~-P I 
I R 
I 
(7) 
The value of R 1 is the number of the study population who are at risk at a specific 
point in time for treatment number one. The standard error for the second 
treatment group would be calculated the same way as the first treatment. If the 
value for z is found to be 1.96 or greater, then there is strong evidence (at the 0.05 
significance level) that the probability of surviving between these two types of 
therapies are different (Streiner, 1995). If the value for z is less than 1. 96 then the 
probability of survival for the two treatments at the point in time does not differ at 
the 0.05 level of significance. 
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Chapter 6 
Oq~anizin~ and Presentin~ Clinical and Economic Data 
This chapter will discuss the three final steps in the pharmacoeconomic 
evaluation of anastrozole and megestrol acetate. It will first describe the 
construction of an anastrozole/megestrol acetate decision model, following which 
it will review the collection, tabulation, and presentation of cost data. A costs and 
outcomes table will be used to organize the clinical and economic information and 
provide the basis for the calculation of cost-effectiveness ratios. 
Decision model. 
The anastrozole and megestrol acetate randomized clinical trial 
information will be used to construct a decision model. The decision model will 
quantify the life years gained for a hypothetical cohort of patients receiving 
anastrozole or megestrol acetate therapies. The model will include clinical events 
that track and quantify the amount of life patients receive over the five year time 
horizon. The clinical events will include the loss of patients to death and the loss 
of patients to drop-out. Patient drop-out may result from disease progression 
and/or drug induced adverse effects. 
A recursive decision tree will be used to track the probability of fatal and 
non-fatal events occurring throughout the five year time horizon using one year 
periods. The probability of fatal events (i.e. , death) for each drug therapy, will be 
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estimated from survival data. The probability of non-fatal events (e.g., patient 
drop-out) will be estimated from drug utilization data obtained from provincial 
cancer agencies, by using epidemiologic information, or by informed guesswork 
(Weinstein, Fineberg et al., 1980). 
Figure 9 illustrates the main branch of the recursive decision tree. 
I Death 1 
Non-Fatal Drop-Out I 
jAnastrozole Fatal 
I mgod 
L 
Megestrol Acetate 
40 mg qid 
Continue Therapy 
Fatal 
Death I I 
Non-Fatal I Drop-Out I 
Continue Therapy 
Fifi:ure 9. Main branch ofthe recursive decision tree for anastrozole 1-mg od and 
megestrol acetate 40-mg qid therapies. 
The main branch starts with a decision node that is represented as a square and is 
the point at which the anastrozole 1-mg od or megestrol acetate 40-mg qid therapy 
is selected. Down the treatment path from the decision node is a chance node. The 
chance node is depicted as a circle and branches out to a fatal event, a non-fatal 
event, and a "continue therapy" path. The fatal event ends with the outcome 
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"death". The non-fatal event ends with the outcome "drop-out". The "continue 
therapy" path represents all patients who would move on to another period of drug 
therapy. The outcome of the non-fatal treatment path is labeled drop-out as 
patients who are considered as using other therapies are still alive and are no 
longer tracked in the model. Patients who drop-out include those who have 
experienced ineffective or intolerable drug therapy. 
Figure 10 shows a five year recursive decision tree for anastrozole and 
megestrol acetate. 
Anastrozole 
1-mgod 
Megestrol 
40-mgqid Continue Therapy 
Year I 
Continue Therapy 
Continue Therapy 
Year 2 
Continue Therap 
Continue Therapy 
Continue Therapy 
Continue Therapy 
Continue Therapy 
Continue Therapy 
Year 3 Year4 Year 5 
Fi~ure 10. Five year recursive decision tree for anastrozole and megestrol acetate. 
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In the five year tree the main branch represents a one year period and is 
repeated five times. Patients who continue therapy from the first year enter the 
second year and distribute between the fatal and non-fatal events and the 
"continue therapy" path. The remaining patients continue to distribute between 
the two events and the one path until the end of the fifth year. 
Determinin~ the cost of therapy. 
Determining costs in a pharmacoeconomic evaluation involves three main 
steps: (1) identifying the types of resources consumed, (2) measuring resource 
consumption, and (3) placing a dollar value on resource consumption. 
Identifying the types of resources consumed can be determined from a 
detailed examination of the events found on the decision tree. The costs attached 
to fatal events, nonfatal events, and the continue therapy path can be separated 
into medical, non-medical and indirect expenses. Medical costs would be divided 
into costs for therapy and costs for treating adverse effects. Non-medical costs 
would include travel expenses, accommodations, food, and telephone. Indirect 
costs would include the loss of earned income by the patient or their families. 
Measuring the costs associated with caring for the patient's additional years of 
life that result from the treatment would not be included. CCOHT A believes that 
"costs associated with persons living longer and consuming health care resources are 
subject to debate" and should not be included (CCOHT A, 1996, p. 12). 
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A detailed review of consumable resource items affecting medical, non-
medical and indirect expense groups will need to be performed. A list of consumable 
resource items and the sources of cost information are provided in Table 5. 
Table 5 
Resource Item List and Sources of Cost Information 
Resource Item Sources of Cost Information Comments 
Physician fees or -Provincial fee schedules. -In some instances, physicians 
salaries -Canadian Institute for Health Information are paid on salary. 
(CIHI) National Physician Database. -Cost per service. 
Nursing services -Victoria Order ofNurses (VON) offices. - Use cost per intervention. 
Clinic services or -VON and fee schedules from provinces. -No classification system for 
Home care -National health expenditure survey. fee schedules in place. 
serv1ces -Could allocate costs for heating, lighting, -Could use hourly rate. 
housekeeping, etc. based on size of clinic. 
Laboratory and -Fee schedules are available from the -Cost/test should be used. 
diagnostic tests provinces. -Private and public costs differ. 
Medical imaging -Provincial fee schedules available. -Use cost/exam. 
Drugs (hospital, -Hospital or cancer clinic pharmacies. -Cost should be at invoice price 
cancer agencies) -Hospital drug contracts. plus overhead charges. 
Drugs (Pharmacy -Patented Medications Prices Review Board -Co-payment must be 
services) and provincial price information. accounted for according to the 
-Individual pharmacies. perspective of the analysis. 
Medical supplies -Retail or manufacturer pricing. -Use cost/item. 
Lost wages -Employer salary costs including benefits. -Use hourly rates. 
Out-of-pocket -Collected by questionnaire Encompass -These costs may include non-
expenses items paid out by patients and/or family . medical costs. 
~From "A Guidance Document for the Costing Process" by, CCOHTA, 
1996, Ottawa: National Library of Canada. pp. 6-11. 
Once resource items have been identified, the next step in the evaluation is 
to determine the dollar values. There are different methods that can be used to 
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determine the value of resource items. Whatever the method chosen, each 
technique "entails a certain amount of complexity, time and effort and yields a 
certain precision" (CCOHTA, 1996, p. 5). CCOHTA (1996) describes the 
challenge of valuing resource items as "strik[ing] the appropriate balance between 
the need for precision and the avoidance of bias and the effort needed to provide 
the increased precision" (p. 5). 
When performing the cost analysis the pharmacoeconomist should 
consider pricing some resource items according to their opportunity cost. The 
opportunity cost is "the value of the foregone benefits because the resource is not 
available for its best alternative use" (Drummond et al. , 1993, p. 41). For 
example, the opportunity cost for a family member to provide home care to an ill 
patient would be the family member' s lost wages, plus any other costs or loss of 
revenue that the family member might incur while providing care. 
The cost per unit of output is useful for evaluating the consumption of 
resources for many items since it assigns a monetary value to the consumption of 
specific resource units. Examples of cost per unit of resource output include cost 
per laboratory test, cost per chest x-ray, cost per 1-mg dose of anastrozole, and 
cost per physician service/intervention. 
Other resource items, like home care or clinic services, can be determined 
from per diem rates. Per diem rates represent a daily average cost per patient for 
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providing the service. These can be multiplied by the average length of stay to 
estimate the total costs (CCOHTA, 1996). 
When collecting resource item expenses the pharmacoeconomist should 
provide a range of costs that can be used in the sensitivity analysis. A range of 
costs can be based on the accuracy of the resource item estimates. 
Table 6 shows the range of resource unit costs for each year of drug 
therapy for a hypothetical case of participants receiving anastrozole 1-mg therapy 
(CCOHTA, 1996). Dollar values are for illustrative purposes only and do not 
represent actual costs (Walker, 1997; Prince George Regional Hospital, 1998). 
Table 6 
Cost Valuation of Continuous Therapy Resource Items 
Resource Unit Year I Year2 Year 3 Year4 Year 5 
Physician fees $285-$305 $190-$220 $190-$220 $190-$220 $190-$220 
Nursing services $135-$150 $90-$100 $90-$100 $90-$100 $90-$100 
Clinic services $360-$440 $240-$305 $240-$305 $240-$305 $240-$305 
Laboratory $30-$35 $20-$25 $20-$25 $20-$25 $20-$25 
Medical imaging $170-$190 $0 $0 $0 $0 
Anastrozole 1-mg od $1740- $1740- $1740- $1740- $1740-
$1790 $1790 $1790 $1790 $1790 
Medical supplies $0 $0 $0 $0 $0 
Lost wages $75-$150 $50-$100 $50-$100 $50-$100 $50-$100 
Out-of-pocket $20-$60 $10-$30 $10-$30 $10-$30 $10-$30 
Total $2815- $2340- $2340- $2340- $2340-
$3120 $2570 $2570 $2570 $2570 
Note: Dollar values are for illustrative purposes only and do not represent actual 
values. From "A Guidance Document for the Costing Process" by, CCOHTA, 
1996, Ottawa: National Library of Canada. p.14. 
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In the case of anastrozole/megestrol acetate, there would be a cost 
valuation table for fatal and non-fatal events and the continuous therapy path, for 
both anastrozole and megestrol acetate therapies. Resource item costs would 
depend on the treatments and the events that are being studied. For example, out-
of-pocket costs would be greater for patients and their families, in fatal and non-
fatal events than in the continuous therapy path. The costs of fatal and non-fatal 
events would be greater because these events would most likely result in more lost 
time from work, greater travel, greater accommodation requirements, higher 
phone costs, and more lost wages. Non-fatal medical costs associated with disease 
progression would be larger than continuous therapy medical costs as these 
patients would require more medical interventions (e.g. laboratory work, 
physician monitoring, nursing support). 
Costs and outcomes table. 
Once resource item costs have been determined, the next step in the 
analysis is to calculate the total costs and the total effectiveness for anastrozole 
and megestrol acetate therapies. Total costs and total effectiveness are calculated 
on the costs and outcomes table by performing a cohort simulation of patients to 
which survival and cost information can be applied (Walker, 1997). The costs and 
outcomes table uses mortality, drop-out, and continuing therapy rates to predict 
the number of patients surviving, the number of patients who died, the number of 
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patients who dropped out, and the number of patients who continued with therapy. 
Once these numbers of patients have been determined, the total survival time and 
the total cost of therapy, for each year of treatment, is then calculated. Survival 
time can be calculated by summing the years that patients are alive. Patients 
receive one-half of a year of survival time for fatal and non-fatal events and a full 
year for each year in the continuous therapy path. 
Table 7 shows the hypothetical costs and outcomes for anastrozole 1-mg 
od therapy while Table 8 shows the hypothetical costs and outcomes for 
megestrol acetate therapy. While the values used in the costs and outcomes table 
do not represent actual values, the table illustrates how total costs and total 
effectiveness, how the cost-effectiveness ratio, and how the incremental cost-
effectiveness ratio can be calculated. 
Cost-Effectiveness Analysis 73 
Table 7 
Hypothetical Costs and Outcomes Table for Anastrozole 1-mg od 
Costs and Outcomes year I year 2 year 3 year 4 year 5 
mortality rate 0.23 0.26 0.39 0.31 0.25 
drop-out rate 0.06 0.06 0.09 0.1 0.1 
continuing therapy rate 0.71 0.68 0.52 0.59 0.65 
costs for death ($/pt) $2,523 $2,285 $2,285 $2,285 $2,285 
costs for drop-out ($/pt) $2,055 $1 ,817 $1 ,817 $1 ,817 $1 ,817 
costs for continuing therapy ($/pt) $2,815 $2,340 $2,340 $2,340 $2,340 
# pts surviving 770 570 348 240 180 
# ofpts died 230 200 222 108 60 
# of pts dropped out 60 46 51 35 24 
# pts continuing therapy 710 524 297 205 156 
total survival time in cohort (life years) 855 647 434 276 198 
total cost in cohort (Canadian$) $2,702,095 $1 ,766,626 $1 ,295,937 $789,228 $545,359 
discount factor (at a 5% discount rate) 0.9524 0.907 0.8638 0.8227 0.7835 
discounted survival time in cohort 814 587 375 227 155 
discounted costs in cohort $2,573,475 $1 ,602,330 $1 ,119,430 $649,298 $427,289 
total survival time for five year treatment (after discounting) 2158 life years 
total cost for five year treatment (after discounting) $6,371 ,822 
Cost-Effectiveness Ratio $2,953/Iife year 
Note: A hypothetical cohort of 1000 patients at day 1. Distribution of patients into 
death and drop-out events, and continue therapy path determined at the end of 
each year of treatment according to mortality, drop-out, and continue therapy 
rates. 
Cost-Effectiveness Analysis 74 
Table 8 
Hypothetical Costs and Outcomes Table of Me~estrol Acetate 40-mg qid 
Costs and Outcomes year I year 2 year 3 year 4 year 5 
mortality rate 0.28 0.36 0.39 0.21 0.18 
drop-out rate 0.05 0.06 0.09 0.09 0.1 
continuing therapy rate 0.67 0.58 0.52 0.7 0.72 
costs for death ($/pt) $2,427 $2,285 $2,285 $2,285 $2,285 
costs for drop-out ($/pt) $1 ,959 $1 ,817 $1 ,817 $1 ,817 $1 ,817 
costs for continuing therapy ($/pt) $2,624 $2,149 $2,100 $2,050 $2,000 
# pts surviving 720 461 281 222 182 
# ofpts died 280 259 180 59 40 
# of pts dropped out 50 43 41 25 22 
# pts continuing therapy 670 418 297 197 160 
total survival time in cohort (life years) 835 569 408 239 191 
total cost in cohort (Canadian $) $2,535,590 $1 ,568,189 $1 ,109,697 $584,208 $451 ,447 
discount factor (at a 5% discount rate) 0.9524 0.907 0.8638 0.8227 0.7835 
discounted survival time in cohort 795 516 352 197 150 
discounted costs in cohort $2,414,896 $1 ,422,347 $958,556 $480,628 $353,709 
total survival time for five year treatment (after discounting) 2009 life years 
total cost for five year treatment (after discounting) $5,630,135 
Cost-Effectiveness Ratio $2,802/life year 
Incremental Cost Effectiveness Ratio (ICER = C 1-CiE 1-E2) $4978/life year gained 
~: Hypothetical cohort of 1000 patients at day 1. Distribution of patients into 
death and drop-out events, and continue therapy path determined at the end of 
each year of treatment according to mortality, drop-out, and continue therapy 
rates. 
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Once total survival time and total cost for the cohort is determined, a 
discount factor is applied to survival and cost data (CCOHT A, 1997). The 
discount factor is multiplied by the cost and survival time for each year of 
treatment (Drummond et al. , 1993). The total survival time and the total cost for 
the five year treatment of the hypothetical cohort of patients are then calculated. 
The cost-effectiveness ratio is determined by dividing the total cost by the 
total survival time for the five year treatment after discounting. The incremental 
cost-effectiveness ratio can be calculated after the cost-effectiveness ratios for 
both drug treatments have been determined. 
The costs and outcomes table also provides a simple way of adjusting 
variables for performing sensitivity analysis. Walker (1997) recommends 
generating the costs and outcomes table on a computer spreadsheet (e.g. Microsoft 
Excel®) and programming the simple mathematical formulas so that, when 
performing sensitivity analysis, the variables can be easily adjusted and the 
calculations can be performed automatically. 
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Chapter 7 
Summary 
This thesis has outlined the methodological techniques for performing a 
cost-effectiveness analysis of anastrozole and megestrol acetate in the treatment of 
progressive breast cancer. The Canadian Coordinating Office for Health 
Technology Assessment (CCOHTA) document "Guidelines for Economic 
Evaluation of Pharmaceuticals" has been used to provide a comprehensive and 
structured approach to the methodological techniques needed in a 
pharmacoeconomic analysis (CCOHTA, 1997). Hopefully, researchers carrying 
out similar pharmacoeconomic studies will find this review useful and will 
encourage effective, efficient, and equitable use of pharmaceutical therapies. 
The principal pharmacoeconomic methodology used to evaluate 
anastrozole versus megestrol acetate was a cost-effectiveness analysis (CEA). The 
CEA of anastrozole/megestrol acetate was selected for two reasons. First, 
researchers have suggested that inequitable resource allocation has occurred in the 
area of palliative cancer therapies and that close evaluation of these therapies 
needs to be performed (Jonsson et al. , 1995). Second, the anastrozole/megestrol 
acetate case has provided an opportunity to describe methodological techniques · 
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that would be useful in measuring the effectiveness of palliative breast cancer 
drug therapies. 
While investigators in the anastrozole/megestrol acetate phase III trials 
reported the findings as two year survival rates and median time to death, the data 
was reevaluated by methods considered by some researchers as being less biased. 
The anastrozole and megestrol acetate survival information was expressed as 
absolute risk reduction and numbers needed to treat. 
The absolute risk reduction for women taking anastrozole 1-mg od for a 
median time of 31 months was found to be 10.2 percent. This indicated that 
women being treated with anastrozole 1-mg od for 31 months had 10.2 percent 
fewer deaths than women treated with megestrol acetate 40-mg four times daily 
( qid) for the same duration. 
The number needed to treat was calculated to be 10, indicating that if 1 0 
women were treated with anastrozole 1-mg od for 31 months, instead of megestrol 
acetate 40-mg qid, one death would be prevented. This demonstrated that 
anastrozole 1-mg od offered a survival advantage over megestrol acetate 40-mg 
qid and that a pharmacoeconomic evaluation of these therapies would be 
worthwhile. However, because the randomized clinical trial data may not reflect 
real-life drug utilization patterns and because the phase III drug trial findings 
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cannot be reliably extrapolated beyond the 31 month median follow-up period, 
these results may not be generalizable. 
Before methodological techniques were reviewed the pharmacoeconomic 
study population was defined, the perspective of the analysis was stated, and the 
time horizon for the analysis was determined. The pharmacoeconomic population 
was defined as women with postmenopausal estrogen receptor positive breast 
cancer whose disease has progressed while on tamoxifen and who have switched 
therapy to either anastrozole 1-mg od or megestrol acetate 40-mg qid. The 
analysis followed the societal perspective as recommended by CCOHT A. The 
time horizon for the analysis was determined to be five years based on efficacy 
data from other hormonal breast cancer therapies. 
In chapter 2 decision modeling methods were discussed. Decision 
modeling was used to systematically organize clinical and economic information 
into a structured framework of events. A standard decision tree, a recursive 
decision tree, and a Markov model were described. A recursive decision tree was 
selected for the analysis of the anastrozole/megestrol acetate case. The recursive 
decision tree comprised a main branch of two events and one treatment path. The 
events selected were "death" and "drop-out", and the path was "continue therapy". 
These events were selected to provide a means of quantifying the survival time 
obtained from each therapy. 
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The main branch of the recursive decision tree represented a one year 
period of therapy. The main branch was repeated five times and formed the five 
year recursive tree. Structuring the tree in this way provided a method of tracking 
the distribution of patients through the five year therapy. At the end of the five 
year horizon the amount of survival time was estimated by summing up the 
amount of life-years for a hypothetical cohort of patients. 
In reviewing the phase III trial data it was found that the 
anastrozole/megestrol acetate 31 month median treatment period was too short by 
CCOHTA' s standards. According to CCOHTA, the ideal time horizon for a 
pharmacoeconomic analysis of survival times should be until all participants in 
the study have died. If this information is not available, then modeled data would 
need to be used. It was determined that modeled data would need to extend the 
phase III trial data from 31 months to at least 60 months according to efficacy 
data from other hormonal therapies. 
In order to determine the likelihood of patients surviving after each year of 
drug therapy, the probability of death had to be determined. In order to calculate 
the probability of death, raw survival data from the phase III trials was needed. 
Raw survival data would provide the analyst with the opportunity to calculate the 
mortality rate, the hazard ratio, the probability density function, and predict 
survivorship beyond the 31 month median time frame. Since raw survival data 
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was not available another method of estimating mortality/survival rates was 
discussed. Survival rates could be estimated by extrapolating the values from the 
survival curves but, while extrapolating survival rates is easy to perform 
mathematically, the validity and the reliability of the findings in the present case 
is too imprecise to justify using this method. 
Once the recursive decision tree was developed, the next step in the 
evaluation was to determine the costs for anastrozole and megestrol acetate 
therapies. The evaluation of costs for therapy encompasses three main steps: 
identifying the types of resources, measuring resource consumption, and 
determining the dollar value of resource consumption. Resource items were 
identified from the events found on the recursive decision tree and were based on 
the societal perspective. A list of resource items, the sources of cost information, 
and specific points to con~ider when measuring those resource items were also 
discussed. Even though costing of resource items was not performed, one method 
for calculating the value of resource items could be determined from cost per unit 
of resource output and per diem rates. When valuing resource items a range of 
costs would be gathered and used in a sensitivity analysis. 
The final stage of the pharmacoeconomic evaluation involved combining 
clinical and economic data into a single table. A sample table of costs and 
outcomes for anastrozole and for megestrol acetate therapies were provided (see 
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Tables 7 and 8). The tables were used to demonstrate how survival time, 
discounting, and cost-effectiveness ratios could be calculated from a hypothetical 
cohort of patients. The data used in the tables did not represent actual values but 
were provided for illustrative purposes only. 
The costs and outcomes table combined mortality, drop-out, and 
continuing therapy rates so as to determine the number of patients in each of the 
three events in years one through five. Costs per patient, determined from the 
consumption of resource items, were then applied to the number of patients in 
each event. Survival times were determined from the number of patients in the 
death and drop-out events, and the continue therapy path. Patients who dropped 
out, or died, were given one-half of a year of survival time. Patients who 
continued with therapy received one full year of survival time. Costs and survival 
times were totaled and a discount rate of five percent would be applied to both 
costs and survival times. The cost-effectiveness ratios, after discounting, was then 
determined. The incremental cost-effectiveness ratio for anastrozole 1-mg od and 
megestrol acetate 40-mg qid was determined from the cost-effectiveness ratios. 
Limitations. 
Performing a retrospective cost-effectiveness analysis from clinical trial 
data poses several problems. The randomized clinical trial efficacy data for 
anastrozole and megestrol acetate was designed to demonstrate a particular 
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primary endpoint and was not intended for secondary pharrnacoeconomic 
analysis. 
The anastrozole and megestrol acetate clinical phase III data were found to 
use a dosing regimen for megestrol acetate that is not normally being prescribed 
in Canada. The clinical trials used a four times daily dosing regimen for ·megestrol 
acetate instead of the more popular daily regimen. Noncompliance with the qid 
dosing regimen is more likely to occur than with the od regimen. If a significant 
portion of patients in the phase III trials was noncompliant then the survival 
results could be compromised. For example, the improved survival times for 
anastrozole may have been a result of better patient compliance than of superior 
pharmacotherapeutic properties of this drug .. 
Further limitations include extending the time horizon of the analysis. 
Extending the time horizon to five years requires modeling procedures that can 
lead to unreliable data. Modeled data for determining the mortality rates for years 
three, four, and five, would have to be thoroughly tested by sensitivity analysis. 
Sensitivity analysis would also need to be applied to drop-out and continue 
therapy rates. Sensitivity analysis would need to be applied to cost valuation of 
resource items and discount rates. The sensitivity analysis would be performed by 
adjusting variables in the costs and outcomes table. 
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While the recursive decision tree provided a method for tracking the 
survival of patients during anastrozole and megestrol acetate therapies, the model 
may be too simplistic for actual use. A more detailed recursive decision tree with 
a greater number clinical events and paths may help to improve the predictability 
of survival for hormonal therapy in palliative breast cancer. 
Future research. 
Although the practice ofpharmacoeconomics is considered in its infancy, 
guidelines for performing and evaluating pharmacoeconomic studies are 
becoming commonplace. Guidelines, such as those developed by CCOHT A, are 
helping to ensure that the methods of economic and clinical evaluation of health 
care programs are based on accepted analytical techniques. Future research will be 
required to illustrate how these guidelines can be used in everyday health care 
practice. For example, health care managers, responsible for the allocation of 
resources, will need to understand how pharmacoeconomics can be used to assist 
in drug policy decision making. 
Since the accuracy and validity of pharmacoeconomic studies is reliant on 
quality data, future pharmacoeconomic research should promote methods of 
obtaining accurate and reliable information. Randomized clinical trials are 
important sources of information but can be of limited value. Randomized clinical 
trials are designed to study drug safety and efficacy under controlled situations, 
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but in pharmacoeconomic evaluations, it is how the drug works in the real world 
that is of importance. Future research should find ways to overcome the pitfalls of 
using randomized clinical trial data in pharmacoeconomic evaluations. 
It would be hoped that the B.C. Cancer Agency and other institutions in 
British Columbia will, in the future, use criteria similar to those of the Therapeutic 
Initiative and the Pharmacoeconomics Iniative in the selection of drugs for 
patients under their care. 
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